These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Oesterling JE Prostate Suppl; 1996; 6():67-73. PubMed ID: 8630233 [TBL] [Abstract][Full Text] [Related]
7. The origin and development of benign prostatic hyperplasia. An age-dependent process. Oesterling JE J Androl; 1991; 12(6):348-55. PubMed ID: 1722790 [TBL] [Abstract][Full Text] [Related]
8. Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue. Lin VK; Wang D; Lee IL; Vasquez D; Fagelson JE; McConnell JD Prostate; 2000 Aug; 44(3):193-203. PubMed ID: 10906735 [TBL] [Abstract][Full Text] [Related]
9. Challenging the Inevitability of Prostate Enlargement: Low Levels of Benign Prostatic Hyperplasia Among Tsimane Forager-Horticulturalists. Trumble BC; Stieglitz J; Eid Rodriguez D; Cortez Linares E; Kaplan HS; Gurven MD J Gerontol A Biol Sci Med Sci; 2015 Oct; 70(10):1262-8. PubMed ID: 25922348 [TBL] [Abstract][Full Text] [Related]
10. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle. Isaacs JT J Steroid Biochem; 1983 Jun; 18(6):749-57. PubMed ID: 6191128 [TBL] [Abstract][Full Text] [Related]
11. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia. Isaacs JT; Coffey DS Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001 [TBL] [Abstract][Full Text] [Related]
12. Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications. Sun F; Crisóstomo V; Báez-Díaz C; Sánchez FM Cardiovasc Intervent Radiol; 2016 Jan; 39(1):1-7. PubMed ID: 26581418 [TBL] [Abstract][Full Text] [Related]
13. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Vickman RE; Franco OE; Moline DC; Vander Griend DJ; Thumbikat P; Hayward SW Asian J Urol; 2020 Jul; 7(3):191-202. PubMed ID: 32742923 [TBL] [Abstract][Full Text] [Related]
14. The overlooked cause of benign prostatic hyperplasia: prostatic urethral angulation. Cho KS; Kim J; Choi YD; Kim JH; Hong SJ Med Hypotheses; 2008; 70(3):532-5. PubMed ID: 17761390 [TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells and the embryonic reawakening theory of BPH. Brennen WN; Isaacs JT Nat Rev Urol; 2018 Nov; 15(11):703-715. PubMed ID: 30214054 [TBL] [Abstract][Full Text] [Related]
16. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. Meigs JB; Mohr B; Barry MJ; Collins MM; McKinlay JB J Clin Epidemiol; 2001 Sep; 54(9):935-44. PubMed ID: 11520654 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas. Yue L; Wang T; Ge Y; Ge M; Zhang C; Hou Q; Wang W; Tian H; Ren B; Du B; Zhang W Prostate; 2019 Feb; 79(3):312-319. PubMed ID: 30450670 [TBL] [Abstract][Full Text] [Related]
18. Effect of gold nanoparticles treatment on the testosterone-induced benign prostatic hyperplasia in rats. Al-Trad B; Aljabali A; Al Zoubi M; Shehab M; Omari S Int J Nanomedicine; 2019; 14():3145-3154. PubMed ID: 31118628 [No Abstract] [Full Text] [Related]